Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist
M Vardanyan, OK Melemedjian, TJ Price, MH Ossipov… - PAIN®, 2010 - Elsevier
Pancreatic pain resulting from chronic inflammation of the pancreas is often intractable and
clinically difficult to manage with available analgesics reflecting the need for more effective
therapies. The mechanisms underlying pancreatitis pain are not well understood. Here, the
possibility that interleukin-6 (IL-6) may promote pancreatitis pain was investigated with TB-2-
081 (3-O-formyl-20R, 21-epoxyresibufogenin, EBRF), a small molecule IL-6 receptor
antagonist that was semi-synthetically derived from natural sources. The potential activity …
clinically difficult to manage with available analgesics reflecting the need for more effective
therapies. The mechanisms underlying pancreatitis pain are not well understood. Here, the
possibility that interleukin-6 (IL-6) may promote pancreatitis pain was investigated with TB-2-
081 (3-O-formyl-20R, 21-epoxyresibufogenin, EBRF), a small molecule IL-6 receptor
antagonist that was semi-synthetically derived from natural sources. The potential activity …